Can NuScale Power (SMR) Stock Reach $11?

NuScale Power Corporation (SMR) develops small modular reactors (SMRs) — compact, factory-built nuclear power plants — and holds a rare U.S. Nuclear Regulatory Commission design approval. But a brutal year has pushed the stock from a 52-week high near $57 to roughly $5.67, as commercial milestones slip and bearish analysts cut targets. The question now is whether SMR can claw back toward a central analyst target of $11.

Key Takeaways

• The central target of $11 is the arithmetic mean of 13 verified, current analyst price targets (approximately $11.31), rounded to a clean level.
• With shares near $5.67, reaching $11 implies roughly 94% upside — a very large required move.
• The target range is unusually wide, from $5 (Barclays) to $20 (Cantor Fitzgerald), reflecting deep disagreement about execution risk.
• Key support factors include roughly $1.9 billion in cash with no debt, a first-of-its-kind NRC-approved design, and a potential 6-gigawatt TVA/ENTRA1 project.
• Key risks include no firm customer commitments, a 99% year-over-year revenue collapse in Q2 2026, share dilution, and projected cash burn.

Analyst Price Targets and Consensus View

Across 13 current targets from identifiable firms, the low-to-high range runs from about $5 to $20. The arithmetic mean is roughly $11.31, rounded to a central target of $11. The most cautious views sit at the bottom: Barclays cut SMR to Underweight with a $5 target on commercial delays, UBS downgraded to Sell with a $6 target in September, and Citi and RBC Capital each hold $7 targets. In the middle, Goldman Sachs ($9), Truist ($10), Bank of America and Texas Capital Securities ($12 each), and HSBC ($13) cluster around Hold ratings. The most constructive names — B. Riley and Canaccord Genuity ($15 each), Northland ($16), and Cantor Fitzgerald ($20) — retain Buy ratings.

The aggregate rating is a consensus "Hold," with roughly four to five Buy-equivalent ratings, seven to eight Holds, and four to five Sells. Bulls argue liquidity and regulatory position justify a mid-teens valuation; bears point to absent firm contracts and slow timelines. Independent data providers report averages in a similar $11.50-to-$13 range, broadly consistent with the $11 figure calculated here.

Current Market Position and Path Toward the Target

At approximately $5.67, SMR would need to appreciate about 94% to reach $11 — a very large move. The stock trades below its 50-day and 200-day moving averages and near 52-week lows. Fundamentals remain early-stage: Q2 2026 revenue collapsed 99% year over year to roughly $75,000, against an operating loss near $65 million. The path toward $11 would likely require conversion of the non-binding TVA/ENTRA1 framework — up to 6 gigawatts using NuScale technology — into a definitive power purchase agreement (PPA), plus progress on the RoPower project in Romania. Without such catalysts, valuation expansion toward the target is difficult to support.

What Could Support a Move Toward the Target

• Regulatory moat: NuScale is the only U.S. company with NRC design approval for a small modular reactor, a meaningful barrier to entry.
• Balance sheet: Roughly $1.9 billion in cash with no debt funds early project work and reduces near-term financing risk.
• Demand backdrop: Surging power needs from AI data centers and decarbonization support the broader nuclear theme.
• TVA/ENTRA1 catalyst: A definitive PPA, even if signed later, could re-rate the pipeline and bring targets in the low-to-mid teens into focus.

What Could Prevent the Target From Being Reached

• No firm commitments: The TVA/ENTRA1 agreement remains non-binding, and Barclays sees a risk negotiations extend into 2027.
• Long timelines: UBS cites a five-year-plus build cycle and no firm customer commitments while competitors are already breaking ground.
• Cash burn and dilution: Analysts project roughly $700 million of cumulative cash burn from 2026 to 2028, alongside a $750 million at-the-market equity program that has already diluted shareholders.
• Revenue collapse and competition: A 99% revenue decline and rivals such as Westinghouse, Rolls-Royce, and GE Vernova with stronger funding weigh on sentiment.

Technical Levels and Market Structure

SMR is in a pronounced downtrend, trading below its 50-day (near $9) and 200-day (near $10) moving averages and setting new 52-week lows. The former 52-week low around $7 has flipped to overhead resistance, followed by the psychological $10 round number. A durable recovery toward $11 would first require reclaiming those levels and establishing a higher low, a structure that has not yet formed.

Time Horizon and What Investors Should Monitor

Analyst price targets typically reflect a roughly 12-month research horizon, though individual assumptions vary. The most important near-term events are NuScale's third-quarter results on November 5 and any update on the TVA/ENTRA1 PPA and the Romanian RoPower project. Investors should also watch cash burn, additional share issuance, and revisions to the roughly $0.12-per-share quarterly loss estimate. None of these offers a definitive forecast of whether the $11 target will be met.

AI Daily Buy/Sell Signals

Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals from changing market conditions, technical behavior, and AI-driven analysis. For a high-volatility name like SMR, the tool can help traders discover opportunities, monitor existing positions, and spot shifting trends more efficiently than manual screening. Explore the AI Daily Buy/Sell Signals to see how automated signals fit into your research process.

Final Assessment

Reaching $11 from roughly $5.67 demands a roughly 94% advance — a very large move that hinges less on valuation and more on converting NuScale's regulatory advantage into a firm, financed contract. The strongest supports are its NRC-approved design, strong cash position, and the potential TVA/ENTRA1 deployment; the principal obstacles are absent firm commitments, long timelines, dilution, and collapsing near-term revenue. With targets spanning $5 to $20, analyst disagreement is extreme, and the central $11 figure is an arithmetic average, not a guarantee. Investors should watch the November 5 earnings call and any definitive PPA announcement as the clearest signals of whether the gap toward $11 can begin to close.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations